Gladstone, Xyphos target universal CARs to latent HIV

Xyphos teamed up with the Gladstone Institutes to direct the company’s universal CAR Ts to cells latently infected with HIV, addressing several of the challenges CAR Ts have faced in the indication.

Major barriers to developing CAR Ts outside oncology include cytotoxicity and high costs. For HIV, an additional challenge has been preventing viral escape (see “CAR Ts Can Move Well Beyond Cancer”)...